From: Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer
Univariate analysis | Multivariate analysis (Cox hazard model) | |||
---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | |
Age | 1.032 (1.004-1.062) | 0.028 | 1.022 (0.994-1.051) | 0.132 |
Sex (female vs. male) | 0.795 (0.427-1.480) | 0.470 | … | … |
ECOG 1 (vs. 0) | 1.679 (0.895-3.149) | 0.107 | 1.552 (0.802-3.002) | 0.192 |
2 (vs. 0) | 0.802 (0.107-5.989) | 0.829 | 0.980 (0.113-8.464) | 0.985 |
Pneumonectomy | 1.176 (0.421-3.290) | 0.757 | … | … |
Tumor size | 0.998 (0.970-1.027) | 0.897 | … | … |
Numbers of dissected lymph nodes | 0.984 (0.960-1.010) | 0.207 | … | … |
Adenocarcinoma (vs. non-adenocarcinoma) | 1.220 (0.675-2.206) | 0.509 | … | … |
Differentiation (moderate to poor vs. well) | 1.675 (0.874-3.211) | 0.120 | … | … |
Lymphovascular invasion | 0.827 (0.322-2.124) | 0.692 | … | … |
Pleural invasion (pl2 and pl1 vs. pl0) | 0.953 (0.458-1.983) | 0.897 | … | … |
Platinum based chemotherapy (vs. no adjuvant therapy) | 0.454 (0.244-0.847) | 0.013 | 0.507 (0.263-0.978) | 0.043 |